Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Journal of the National Cancer Institute|October 30, 2008
Antitumor efficacy testing in rodentsMelinda G Hollingshead
Anticancer Research|September 15, 2005
NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenograftsMaria V Papadopoulou, William D Bloomer, Melinda G Hollingshead
Journal of Experimental Therapeutics & Oncology|November 6, 2002
Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenograftsMaria V Papadopoulou, Ming Ji, William D Bloomer, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2002
Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing miceMaria V Papadopoulou, Ming Ji, Xinhai Ji, et al.
BMC Cancer|February 24, 2009
ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKCLuke H Stockwin, Sherry X Yu, Howard Stotler, et al.
Journal of Medicinal Chemistry|June 25, 2005
A new synthetic agent with potent but selective cytotoxic activity against cancerWieslaw M Cholody, Teresa Kosakowska-Cholody, Melinda G Hollingshead, et al.
Radiation Research|August 29, 2007
Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenograftsMaria V Papadopoulou, William D Bloomer, Alice P Taylor, et al.
BMC Biotechnology|December 20, 2011
Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenograftsSergio Y Alcoser, David J Kimmel, Suzanne D Borgel, et al.
Pageof 7